DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restriction
Applicant’s election without traverse of Invention I and species of CDRs 24-29, in the reply filed on 03SEP2026 is acknowledged.
All claims drawn to alternative Inventions and/or species have been cancelled in the amendments file 03SEP2026.
Claim Status
Claims 1-21 have been canceled.
Claims 22-40 are new.
Claims 22-40 are pending in the instant application and examined on the merits (i.e., Claim 22 is independent).
Priority
The present application claims priority under 35 U.S.C. 119 (a)-(d). The certified copies of European patent application No. EP22202154.5 filed on 18OCT2022 and European patent application No. EP23172910.4 filed on 11MAY2023 have been received and are acknowledged.
Information Disclosure Statement
The information disclosure statement(s) (IDS) submitted on 02APR2024, 03SEP2026, and 16SEP2026 is/are acknowledged and the references cited therein have been considered.
Specification
The disclosure is objected to because of the following informalities:
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (see for example ¶0014). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Appropriate correction is required.
Claim Objections
Claims 27, 30, 32-33, and 38-39 are objected to because of the following informalities:
Claims 27 and 38 should be amended to replace “an” with “the” prior to “amino acid sequence….” in lines 1 and 2 of the claims.
Claim 30 should be amended to “substitutions” and “positions of” in line 2 of the claim.
Claim 32 should be amended to add “the amino acid sequence of” between “…comprising” and “SEQ ID NO:….” in two places in line 2 of the claim.
Claim 33 should be amended to “…as an IgG1, comprising Fc-silencing mutations of leucine (L) to alanine (A) substitutions (LALA mutation) at the positions of 234 and 235 according to EU numbering in CHO cells.” or something of similar nature.
Claim 39 should be amended to “substitutions” and “positions of” in line 3 of the claim.
Appropriate correction is required.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 22-40 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of co-pending Application No. 18/489605 (i.e., same priority date); herein referred to as the “reference application.” Although the claims at issue are not identical, they are not patentably distinct from each other because the anti-NaPi2b antibody drug conjugate of claim 6 of the reference application is an obvious variant of the anti-NaPi2b antibody drug conjugate of claim 22 of the instant application.
The co-pending claims of the reference application recite:
PNG
media_image1.png
438
651
media_image1.png
Greyscale
….
PNG
media_image2.png
237
660
media_image2.png
Greyscale
….
PNG
media_image3.png
289
646
media_image3.png
Greyscale
….
PNG
media_image4.png
420
656
media_image4.png
Greyscale
With regards to instant claims 22-27, 31-32, and 34-38:
The main difference between claims 1 and 6 of the reference application and claim 22 of the instant application is that the reference application claims are drawn to an anti-NaPi2b antibody which is defined by function rather than structure and a generic ADC comprising the anti-NaPi2b which lacks a specific structure.
In this instance, because reference application claims 1 and 6 are silent on the antibody drug conjugate comprising HCDRs1-3 and LCDRs1-3 having the amino acid sequence of SEQ ID NOs: 24-26 and 27-29, respectively and a P5(PEG24)-VC-PAB-Exatecan linker-drug conjugate, the specification was consulted to determine the scope of the generic term of anti-NaPi2b antibody and drug conjugate. Per the reference application claims 2(a) and 3(a), the anti-NaPi2b antibody which is capable of a) through e) of reference application claim 1, comprises a VH and VL of SEQ ID NOs: 4 and 5, respectively or a LC and HC SEQ ID NOs: 6 and 7, respectively or HCDRs1-3 and LCDRs1-3 of SEQ ID NOs: 24-26 and 27-29, respectively. Reference application SEQ ID NOs: 4-7 and 24-29 are 100% query match to SEQ ID NOs: 4-7 and 24-29, respectively of the instant application (see OA.APPENDIX). With regards to the ADC, the p 37 of the reference specification teaches that the ADC having the formula selected from the group consisting of a) Formula I:…
PNG
media_image5.png
181
437
media_image5.png
Greyscale
… p) Formula XVI…. Thus, the generic anti-NaPi2b ADC of reference claims 1 and 6 encompass the species of instant claims 22-27, 31-32, and 34-38.
With regards to instant claims 28-30 and 39:
The main difference between claims 1 and 6 of the reference application and claims 28-30 and 39 of the instant application is that the reference application claims are drawn to an anti-NaPi2b antibody which is defined by function rather than structure and a generic ADC comprising the anti-NaPi2b which lacks a specific structure.
In this instance, because reference application claims 1 and 6 are silent on the anti-NaPi2b ADC comprising HCDRs1-3 and LCDRs1-3 having the amino acid sequence of SEQ ID NOs: 24-26 and 27-29, respectively, a P5(PEG24)-VC-PAB-Exatecan linker-drug conjugate, and that the anti-NaPi2b antibody is a humanized monoclonal NaPi2b-specific IgG1 antibody comprising Fc silencing mutations comprising LALA mutations the specification was consulted to determine the scope of the generic term of anti-NaPi2b antibody and drug conjugate. As discussed supra, the dependent claims teach the six nondegenerate CDRs of the antibody and the specification teaches the linker-drug conjugate. Regarding the additional limitations, reference application dependent claim 4a, 4b), 4d), and 4g) teaches that the anti-NaPi2b antibody which is capable of a) through e) of reference application claim 1 has one or more of the following characteristics a monoclonal antibody, a chimeric or humanized antibody, human IgG antibody, optionally a human IgG1 antibody, comprising Fc silencing mutations such as LALA mutations at the positions 234 and 235, etc.. Therefore, the generic anti-NaPi2b ADC of reference claims 1 and 6 encompass the species of instant claims 28-30 and 39.
With regards to instant claim 33:
Furthermore, the main difference between claims 1 and 5 or 6 of the reference application and claim 33 of the instant application is that the reference application claims are drawn to a nucleic acid which encodes an anti-NaPi2b antibody which is defined by function rather than structure or a generic ADC comprising the generic anti-NaPi2b which lacks a specific structure; and in reference application claims 5 or 6 there is no recitation of the species being expressed in CHO cells.
In this instance, the claimed product-by-process is an ADC comprising the anti-NaPi2b antibody of SEQ ID NOs: 24-29 and a P5(PEG24)-VC-PAB-Exatecan linker-drug conjugate, wherein the anti-NaPi2b antibody is an IgG1 antibody comprising LALA mutations and is expressed (i.e., produced) in CHO cells. Per MPEP §2113, even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself (i.e., the patentability of the product does not depend on its method of production). Given that the reference application claims 1, 5, and 6 encompasses a nucleic acid encoding the anti-NaPi2b antibody product, which can be used to express the antibody in a host cell (i.e., recombinant antibody production, in for example a CHO cell) and the anti-NaPi2b antibody which is capable of a) through e) of reference application claim 1 has one or more of the following characteristics a monoclonal antibody, a chimeric or humanized antibody, human IgG antibody, optionally a human IgG1 antibody, comprising Fc silencing mutations such as LALA mutations at the positions 234 and 235, etc., the reference application is an obvious variant of instant claim 33.
With regards to instant claim 40:
The main difference between claims 1 and 6 or 7 of the reference application and claim 40 of the instant application is that the reference application claims are drawn to a generic ADC comprising the generic anti-NaPi2b which lacks a specific structure or a composition or a kit comprising (i.e., open language) the generic anti-NaPi2b which lacks a specific structure.
In this instance, because reference application claims 1 and 6 are silent on the anti-NaPi2b ADC comprising HCDRs1-3 and LCDRs1-3 having the amino acid sequence of SEQ ID NOs: 24-26 and 27-29, respectively, and a P5(PEG24)-VC-PAB-Exatecan linker-drug conjugate, and because reference application claims 1 and 7 are silent on the compositions the specification was consulted to determine the scope of the generic term of anti-NaPi2b antibody and drug conjugate and composition. As discussed supra, the dependent claims teach the six nondegenerate CDRs of the antibody and the specification teaches the linker-drug conjugate. Regarding the composition limitations, the specification teaches that it is envisaged to administer the NaPi2B antibodies and/or ADCs of the present invention in the form of a pharmaceutical composition, particularly referring to a composition suitable for administering to humans and/or contains components which are pharmaceutically acceptable (¶00143-00144). Therefore, the generic anti-NaPi2b ADC of reference claims 1 and 6 and the composition or kit of claims 1 and 7 encompass the species of instant claim 40.
In this instance, because both the reference and instant application comprise the ADC comprising the antibody comprising SEQ ID NOs; 24-29 and the linker-drug conjugate of P5(PEG24)-VC-PAB-Exatecan, there is no clear difference in the scope between the products of the reference and instant applications. In response, it is suggested that applicant either file a terminal disclaimer or amend the claims such that a clear and unmistakable line of separation exists between the products claimed in the instant application and those of the reference application.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMANTHA L. HOPKINS whose telephone number is (703)756-4666. The examiner can normally be reached Mon-Thurs 6:00 AM to 4:00 PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached at (571)272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SAMANTHA LAKE HOPKINS/Examiner, Art Unit 1641
/MISOOK YU/Supervisory Patent Examiner, Art Unit 1641